Under 10% of individuals that would benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it releases its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for broader and more equitable availability to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our new guidance recognises that obesity is a long-term condition that can be treated with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key hurdles to widespread access to the injections that can aid individuals in losing considerable weight, says the body.
Skinny Jab Shortage
Even in the present most favorable scenario, the production of these medications might only reach approximately 100 million people – less than 10% of the global need, according to the health organization.
The guideline calls on countries and companies to increase access, through approaches including licensing agreements.
A patent on semaglutide – the primary component of the drug Wegovy – is due to expire in a number of countries in 2026.
How Obesity Jabs Function
These medications replicate a biological compound to delay gastric emptying, curb appetite and boost the sense of being full so individuals eat less.
Individuals typically start to lose weight within a few weeks of commencing the weekly injections.
Evidence indicates people may regain a significant portion a year later of discontinuing the medication, because their normal hunger come back.
Being above a healthy weight increases your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.
